Dynavax Technologies Co. (DVAX) Receives Average Recommendation of “Hold” from Analysts

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have been assigned a consensus rating of “Hold” from the eight brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $28.00.

Several brokerages have recently issued reports on DVAX. BidaskClub downgraded Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Friday. Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cantor Fitzgerald boosted their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Finally, Cowen reissued a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd.

Dynavax Technologies (NASDAQ DVAX) opened at $15.65 on Monday. The stock has a market capitalization of $948.33, a P/E ratio of -7.98 and a beta of 1.31. Dynavax Technologies has a 52-week low of $3.70 and a 52-week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business’s revenue was down 68.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.90) earnings per share. research analysts expect that Dynavax Technologies will post -1.72 EPS for the current fiscal year.

In related news, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the sale, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The disclosure for this sale can be found here. 2.90% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in DVAX. Cubist Systematic Strategies LLC raised its holdings in Dynavax Technologies by 54.5% during the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares in the last quarter. Legal & General Group Plc raised its holdings in Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Dynavax Technologies by 474.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 5,880 shares in the last quarter. Family Management Corp increased its holdings in shares of Dynavax Technologies by 72.7% in the second quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 8,000 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Dynavax Technologies by 17.0% in the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 2,975 shares in the last quarter. 70.54% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/22/dynavax-technologies-co-dvax-receives-average-recommendation-of-hold-from-analysts.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply